Cutting edge metagenomics sequencing combined with advanced bioinformatics enables us to identify trillions of bacterial organisms and predict their activity and role in immune related functions in our bodies. We have developed a proprietary knowledgebase of over 800 associations between the human gut bacteria and diseases. Through our advanced metagenomic analysis platform, we combine this knowledge with one’s individual microbiome. This allows us to capture the state of the microbiome with one test and learn how the microbiome affects a patient’s health and influences diseases.
Well funded European company with a dedicated team of experts in areas of microbiome, software development, business and finance.
Worldwide first ISO 13485:2016 and 9001:2015 certified company in the microbiome field.
We are combining microbiome diagnostics and machine learning to decipher one of today’s most challenging approaches to advance personalized cancer treatments.
In cooperation with five European universities and multiple top tier hospitals BiomeDiagnostics is involved in several clinical studies working on the next evolution of microbiome diagnostics. Our aim is to develop medically-certified products that lead the way to future personalized treatments. After a decade of research BiomeDiagnostics is planning to launch its first diagnostic tool to the market in 2021.
Our focus lies on two clinical indications which are at the current state undisclosed. For further information and updates on the progress of our research program please sign up in the form below.
Our mission is to advance personalized healthcare
by providing healthcare professionals with
world-class microbiome diagnostics.
The company is privately held and well-financed by a group of committed investors that are united with the founding team by their shared vision of building next generation diagnostics products based on the power of artificial intelligence.
Our international leadership team, board of directors and advisory board have substantial experience and expertise in the areas of microbiome research, finance and technology. Together we are proud to work on life-transforming diagnostic products linked to the intestinal microbiome.
As safety and health of patients are the top priorities for BiomeDiagnostics, the company recently certified according to ISO 9001 (Quality management systems) and ISO 13485 (Medical devices). This enables BiomeDiagnostics to be globally the first company in the area of microbiome that holds both ISO certifications.